FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285018506> ?p ?o ?g. }

• W4285018506 abstract "To evaluate the safety and effectiveness of nimotuzumab in combination with chemoradiotherapy for locally advanced cervical esophageal squamous cell carcinoma.Retrospective analysis was conducted from September 2012 to February 2017 among 50 locoregional-advanced cervical esophageal carcinoma (CEC) patients who received concurrent chemoradiotherapy (CRT) combined with or without nimotuzumab at Ningbo Medical Center Lihuili Hospital. Intensity-modulated radiotherapy (IMRT) was administrated on all patients. All patients were divided into two groups, of which 26 (Group A) received 200 mg (22 of 50) or 400 mg (4 of 50) of nimotuzumab per week with CRT and 24 (Group B) received definitive CRT.The median follow-up time was 23 months. The median overall survival (OS) and progression-free survival (PFS) were 40.6 and 21.1 months for all, respectively. The 1-, 2-, and 3-year OS rates on the whole were 79.6%, 62.1%, and 47.8%. There was no statistical difference in overall response rate and disease control rate between the two groups. Patients treated with nimotuzumab (group A) had better PFS than the definitive CRT group (group B) (P < 0.05). However, the median OS was 41.4 months in group A and 32.4 months in group B, respectively (P = 0.517). Multivariate analysis showed that PFS among those with lower Eastern Cooperative Oncology Group (ECOG) score (HR = 5.11; P < 0.01), stage II (HR = 9.52; P < 0.01) and the application of nimotuzumab combined with CRT (HR = 0.16; P < 0.01) was much longer. Furthermore, ECOG, stage, C-reactive protein (CRP) baseline, and histological grade can also be used as independent predictors of OS. Grade >3 adverse reactions were not observed. The most common adverse event related to nimotuzumab was mild fever and the occurrence rate was 19% (5 of 26). The incidence of anemia was 65.4% in group A and 87.5% in group B (P < 0.05).For locoregional-advanced CEC, nimotuzumab combined with IMRT and concomitant chemotherapy was tolerated and effective. In addition, patients with a normal pretherapeutic serum CRP level (CRP < 10 mg/L) can achieve better OS." @default.
• W4285018506 created "2022-07-12" @default.
• W4285018506 creator A5021749487 @default.
• W4285018506 creator A5044293756 @default.
• W4285018506 creator A5047748578 @default.
• W4285018506 creator A5056437521 @default.
• W4285018506 creator A5067714171 @default.
• W4285018506 creator A5083539564 @default.
• W4285018506 creator A5086963026 @default.
• W4285018506 creator A5087631945 @default.
• W4285018506 creator A5087648864 @default.
• W4285018506 date "2022-07-06" @default.
• W4285018506 modified "2023-10-17" @default.
• W4285018506 title "The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study" @default.
• W4285018506 cites W1490708659 @default.
• W4285018506 cites W1491517465 @default.
• W4285018506 cites W1908082413 @default.
• W4285018506 cites W1944436823 @default.
• W4285018506 cites W1957194715 @default.
• W4285018506 cites W1976830577 @default.
• W4285018506 cites W1980211974 @default.
• W4285018506 cites W1980599927 @default.
• W4285018506 cites W1984700444 @default.
• W4285018506 cites W1990736053 @default.
• W4285018506 cites W2015947514 @default.
• W4285018506 cites W2024736353 @default.
• W4285018506 cites W2031915840 @default.
• W4285018506 cites W2048052317 @default.
• W4285018506 cites W2060631221 @default.
• W4285018506 cites W2060819673 @default.
• W4285018506 cites W2060875961 @default.
• W4285018506 cites W2063705700 @default.
• W4285018506 cites W2075085205 @default.
• W4285018506 cites W2083115221 @default.
• W4285018506 cites W2087154405 @default.
• W4285018506 cites W2099918668 @default.
• W4285018506 cites W2105499507 @default.
• W4285018506 cites W2108572537 @default.
• W4285018506 cites W2113814947 @default.
• W4285018506 cites W2115131874 @default.
• W4285018506 cites W2139962184 @default.
• W4285018506 cites W2151809893 @default.
• W4285018506 cites W2156536264 @default.
• W4285018506 cites W2165879808 @default.
• W4285018506 cites W2166559675 @default.
• W4285018506 cites W2166693531 @default.
• W4285018506 cites W2180166158 @default.
• W4285018506 cites W2215752430 @default.
• W4285018506 cites W2265029431 @default.
• W4285018506 cites W2272984102 @default.
• W4285018506 cites W2287555689 @default.
• W4285018506 cites W2318747725 @default.
• W4285018506 cites W2329444697 @default.
• W4285018506 cites W2558487825 @default.
• W4285018506 cites W2580827699 @default.
• W4285018506 cites W2724177236 @default.
• W4285018506 cites W2724558203 @default.
• W4285018506 cites W2757609263 @default.
• W4285018506 cites W2780006105 @default.
• W4285018506 cites W2780483150 @default.
• W4285018506 cites W2920946285 @default.
• W4285018506 cites W2972645840 @default.
• W4285018506 cites W3022592600 @default.
• W4285018506 cites W78954476 @default.
• W4285018506 doi "https://doi.org/10.3389/fonc.2022.905422" @default.
• W4285018506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35898885" @default.
• W4285018506 hasPublicationYear "2022" @default.
• W4285018506 type Work @default.
• W4285018506 citedByCount "0" @default.
• W4285018506 crossrefType "journal-article" @default.
• W4285018506 hasAuthorship W4285018506A5021749487 @default.
• W4285018506 hasAuthorship W4285018506A5044293756 @default.
• W4285018506 hasAuthorship W4285018506A5047748578 @default.
• W4285018506 hasAuthorship W4285018506A5056437521 @default.
• W4285018506 hasAuthorship W4285018506A5067714171 @default.
• W4285018506 hasAuthorship W4285018506A5083539564 @default.
• W4285018506 hasAuthorship W4285018506A5086963026 @default.
• W4285018506 hasAuthorship W4285018506A5087631945 @default.
• W4285018506 hasAuthorship W4285018506A5087648864 @default.
• W4285018506 hasBestOaLocation W42850185061 @default.
• W4285018506 hasConcept C121608353 @default.
• W4285018506 hasConcept C126322002 @default.
• W4285018506 hasConcept C143998085 @default.
• W4285018506 hasConcept C146357865 @default.
• W4285018506 hasConcept C151730666 @default.
• W4285018506 hasConcept C167135981 @default.
• W4285018506 hasConcept C2776055544 @default.
• W4285018506 hasConcept C2778424827 @default.
• W4285018506 hasConcept C2779438470 @default.
• W4285018506 hasConcept C38180746 @default.
• W4285018506 hasConcept C509974204 @default.
• W4285018506 hasConcept C71924100 @default.
• W4285018506 hasConcept C86803240 @default.
• W4285018506 hasConcept C90924648 @default.
• W4285018506 hasConceptScore W4285018506C121608353 @default.
• W4285018506 hasConceptScore W4285018506C126322002 @default.
• W4285018506 hasConceptScore W4285018506C143998085 @default.
• W4285018506 hasConceptScore W4285018506C146357865 @default.
• W4285018506 hasConceptScore W4285018506C151730666 @default.
• W4285018506 hasConceptScore W4285018506C167135981 @default.

• next